Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 11, 2024

Assessment of Measurable Residual Disease Using Patient-Specific Markers and Outcomes After HSCT for Myelodysplastic Syndrome

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol 2024 Jan 17;[EPub Ahead of Print], M Tobiasson, T Pandzic, J Illman, L Nilsson, S Weström, E Ejerblad, G Olesen, A Björklund, A Olsnes Kittang, O Werlenius, F Lorentz, B Rasmussen, J Cammenga, D Weber, C Lindholm, J Wiggh, M Dimitriou, AE Moen, L Yip Lundström, L von Bahr, K Baltzer-Sollander, M Jädersten, S Kytölä, G Walldin, P Ljungman, K Groenbaek, S Mielke, SEW Jacobsen, F Ebeling, L Cavelier, L Smidstrup Friis, I Dybedal, E Hellström-Lindberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading